- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04536610
Is Osteoporosis Education Effective in Parkinsonian Patients
The Effect Of Osteoporosis Education On Osteoporosis Knowledge Level and Daily Life In Parkinsonian Patients, Randomized Controlled Trial
The effects of osteoporosis (OP) education on OP patients and the normal population studied and described in numerous studies. But the effects of OP education on Parkinsonian patients have not been sufficiently elucidated.
The purpose of this study was to evaluate the effect of OP education on the OP knowledge level and daily life in Parkinsonian patients.
Our hypothesis is; to Parkinsonian patients; there is a statistically significant difference in terms of OP knowledge level and daily life between giving only informative leaflets about OP and also providing structured OP education.
54 participants aged 50 and older with Parkinson's Disease were randomized to the experimental and control groups. While only leaflets were given to the control group, structured OP education was also given to the experimental group. Patients were evaluated with the same structured face-to-face interviews at the entrance and 12 weeks later.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The OP education was performed in groups of 4-5 people by a single physician in the form of verbal expression via slide, with a duration of 20 minutes and in the form of a single session. Our leaflets contained the same information as the OP education program.
Face-to-face interviews include; Revised 2011 Osteoporosis Knowledge Test (rOKT) (0-32 points) for OP knowledge levels; National Osteoporosis Foundation daily calcium intake scale [NOF, (mg)], Physical Activity Scale For The Elderly (PASE, 0-763 points), smoking and alcohol use status (Yes/No) and quantities (cigarette pack/per week, alcohol unit/per week), frequency of falls (times/last 1 month) were questioned for effects on daily life.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
İzmir, Turkey
- Dokuz Eylül University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male and female patients aged 50 years or older
- Being diagnosed with Parkinson's Disease
Exclusion Criteria:
1. Severe physical and cognitive dysability
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Experimental group
Providing structured OP education in addition to the informative leaflet.
(The leaflet contained the same information as the OP education program)
|
The OP education was performed in groups of 4-5 people by a single physician with a single session in the form of verbal expression via slide, with a duration of 20 minutes.
Leaflets containe the same information as the OP education program
|
Active Comparator: Control group
Giving only the informative leaflet.
(The leaflet contained the same information as the OP education program)
|
Leaflets containe the same information as the OP education program
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Physical Activity Scale For The Elderly score at the endpoint
Time Frame: At 12th week
|
(0-763 points) Higher scores mean a better outcome
|
At 12th week
|
National Osteoporosis Foundation daily calcium intake scale score at the endpoint
Time Frame: At 12th week
|
(250mg - ... mg) Higher scores mean a better outcome
|
At 12th week
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Revised 2011 Osteoporosis Knowledge Test score at the endpoint
Time Frame: At 12th week
|
(0-32 points) Higher scores mean a better outcome
|
At 12th week
|
Smoking and alcohol use status at the endpoint
Time Frame: At 12th week
|
(Yes/No) "No" is a better status
|
At 12th week
|
Amount of smoking and alcohol use at the endpoint
Time Frame: At 12th week
|
(Cigarette pack / per week, alcohol unit / per week).
Lower scores mean a better outcome
|
At 12th week
|
Frequency of falls at the endpoint
Time Frame: At 12th week
|
Times / last 1 month
|
At 12th week
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Kerim OP Parkinson
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson Disease
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Michele Tagliati, MDRecruitingREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Cedars-Sinai Medical CenterEnrolling by invitationREM Sleep Behavior Disorder | Symptomatic Parkinson Disease | Pre-motor Parkinson DiseaseUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
-
Merck Sharp & Dohme LLCCompletedParkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease
-
University of DeustoCompletedPARKINSON DISEASE (Disorder)Spain
Clinical Trials on Providing structured osteoporosis education
-
Brigham and Women's HospitalNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedOsteoporosis | Osteoporosis, PostmenopausalUnited States
-
University of Southern DenmarkNational Research Center for Bone HealthEnrolling by invitation
-
University of AdelaideOsteoporosis SACompleted
-
Sheffield Teaching Hospitals NHS Foundation TrustSheffield Hallam University; University of York; University of StirlingCompletedPeripheral Arterial DiseaseUnited Kingdom
-
Aydin Adnan Menderes UniversityCompleted
-
University of JenaNovartisUnknownChronic Kidney DiseaseGermany
-
Hospital de Clinicas de Porto AlegreCompleted
-
University of LeicesterSociety for EndocrinologyCompletedPolycystic Ovary SyndromeUnited Kingdom
-
VA Office of Research and DevelopmentCompleted
-
University Hospitals, LeicesterNational Institute for Health Research, United Kingdom; University of LeicesterCompleted